-+ 0.00%
-+ 0.00%
-+ 0.00%

Bicycle Therapeutics doses first patient in Phase 2 pancreatic cancer trial for nuzefatide pevedotin

PUBT·04/20/2026 11:00:32
Listen to the news
Bicycle Therapeutics doses first patient in Phase 2 pancreatic cancer trial for nuzefatide pevedotin
  • Bicycle Therapeutics reported Phase 1/2 combination results for nuzefatide pevedotin with nivolumab in previously treated metastatic urothelial cancer, with data already presented at AACR 2026.
  • Early findings showed encouraging anti-tumor activity in patients whose tumors expressed EphA2, with tolerability described as differentiated versus prior EphA2-targeted approaches.
  • Bicycle selected 8 mg/m² every two weeks as preferred monotherapy dose based on dose-ranging work, positioning it for next-stage development.
  • Enrollment started in March 2026 for a Phase 2 study in recurrent pancreatic ductal adenocarcinoma, with first patient dosed in April 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202604200700BIZWIRE_USPR_____20260420_BW953740) on April 20, 2026, and is solely responsible for the information contained therein.